progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. engages in the research and development of biotechnology product candidates in the areas of oncology and therapeutics worldwide. The company offers RELISTOR (methylnaltrexone bromide), a subcutaneous injection for the treatment of opioid induced constipation (OIC) in patients with advanced illnesses, such as cancer, as well as for the treatment of OIC in patients with non-cancer pain; and RELISTOR-Oral, which has completed Phase III testing for the treatment of OIC in patients with non-cancer pain. It also provides oncology medicines, including PSMA ADC that is in Phase II testing for treatment of prostate and other cancers; and MIP-1404, which is in Phase II testing for imaging agent for prostate cancer; and Azedra for the treatment of pheochromocytoma and paraganglioma, and Neuroblastoma. PSMA ADC is an antibody-drug conjugate (ADC) that targets prostate specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells, as well as on the neovasculature of various other types of solid tumors. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of RELISTOR worldwide other than Japan. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

progenics pharmaceuticals (PGNX) Top Compensated Officers